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KSHV inﬂammatory cytokine syndrome (KICS) is a newly described condition characterized by systemic
illness as a result of systemic, lytic KSHV infection. We used Illumina sequencing to establish the DNA
vironome of blood from such a patient. It identiﬁed concurrent high-level viremia of human
herpesvirus (HHV) 8 and 6a. The HHV8 plasma viral load was 5,300,000 copies/ml, which is the
highest reported to date; this despite less than ﬁve skin lesions and no HHV8 associated lymphoma.
This is the ﬁrst report of systemic HHV6a/KSHV co-infection in a patient. It is the ﬁrst whole genome
KSHV sequence to be determined directly from patient plasma rather than cultured or biopsied tumor
material. This case supports KICS as a new clinical entity associated with KSHV.
& 2012 Elsevier Inc. All rights reserved.Introduction
Kaposi sarcoma (KS) and the plasmablastic variant of multi-
centric Castleman disease (MCD) are associated with Kaposi
sarcoma-associated herpesvirus (KSHV) infection and occur with
increased prevalence in AIDS patients. KS remains among thell rights reserved.
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D.P. Dittmer).leading causes of death for people living with HIV/AIDS today. It is
the most frequent cancer overall in many sub Saharan countries
(e.g. Uganda) (Franceschi et al., 2008). Since skin KS lesions are
relatively easy to diagnose clinically, KSHV viral load assays are
seldom conducted. KSHV gene transcription in KS is variable, but
predominantly restricted to the latent viral genes (Dittmer, 2003,
2011). Compared to diseases caused by other herpesviruses
(HSV-1, HCMV, EBV) systemic viremia in KS is an order of
magnitude less (Lin et al., 2009). As a consequence, infectious
virus has not been efﬁciently recovered from patients, perhaps
due to comparatively low systemic viremia vis-a-vis other her-
pesviruses. There exists a gap in our knowledge as all known
sequence information for KSHV was derived from cell line
propagated or tumor derived clones, but not from free virus
systemically replicating in the natural host.
MCD is a hyperproliferative B cell disorder. MCD patients
express high levels of viral IL6 (vIL6) and human IL6, which are
thought to be responsible for the systemic illness and inﬂamma-
tory symptoms (Brandt et al., 1990; Oksenhendler et al., 2000).
Clinical symptoms of MCD include edema, weight loss, pleural
effusion (mostly cell free, as opposed to PEL), anemia, thrombo-
cytopenia, lymphadenopathy, and splenomegaly (reviewed in
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systemic inﬂammatory response syndrome (SIRS), which can
cause rapid death in AIDS patients. It is thought of as an extreme,
uncontrolled, cytokine-mediated response to infection in CD4
deﬁcient patients. The underlying trigger of this response is
typically unknown. Thus, symptomatic treatment remains the
only option.
KSHV inﬂammatory cytokine syndrome (KICS) has been
recently been proposed as a new KSHV associated disease
(Uldrick et al., 2010). The six patients originally described had
no evidence of MCD despite thorough examination, and no
development of MCD upon follow up. However, they presented
with clinical inﬂammatory syndromes as seen in MCD, high
human IL6 levels, and high systemic KSHV viral load. The patient
described here had the highest systemic KSHV viral load on
record to date, with no identiﬁable MCD. He ﬁts the novel clinical
description for KICS and we were able to establish the complete
DNA vironome from blood.
Systemic KSHV–HHV6a co-infection was uncovered by next
generation sequencing of peripheral blood mononuclear cells and
plasma. We obtained a complete KSHV genome sequence from
high titer, replicating virus rather than tumor associated or tissue
culture propagated variants (Depledge et al., 2011; Lin et al.,
2012), which in the case of KSHV tend to replicate extremely
poorly and may have accumulated mutations.Results
The patient is a 42-year old Caucasian male who was diag-
nosed with human immunodeﬁciency virus (HIV) infection in
1993 and treated with zidovudine/lamivudine and nevirapine. He
discontinued medication in 2003, when his HIV-1 viral load was
undetectable. He presented in December 2008 with a HIV-1 viral
load of 600,000 copies/ml and a CD4 count of 27 cells/ml, and met
the clinical criteria for SIRS. The deﬁnition of SIRS is based on
clinical parameters of systemic inﬂammation not unlike KICS, but
typically does require an association with a speciﬁc infectious
agent.
First, we tested for the presence of typical infectious agents. Stool
for clostridium difﬁcile and sputum for pneumocystis jirovecii were
negative. Serology studies for cryptococcus, toxoplasma, mycobac-
teria, and syphilis as well as urine histoplasma antigen were also
negative. Epstein–Barr-virus loads (EBV) and human cytomegalo-
virus loads (HCMV) were negligible witho250 copies/ml and 647
copies/ml, respectively. The IL6 level was 54.1 pg/ml. In the absence
of AIDS deﬁning infections (and of CD4 T cells), we asked why would
this patient show evidence of a severe, systemic inﬂammatory
reaction?
Excisional axillary lymph node biopsy showed effacement of
the expected architecture, with general lymphocyte depletion,
increased numbers of mature-appearing interfollicular plasma
cells, and disrupted lymphoid follicles typical of HIV lymphade-
nitis (histologic pattern B). There were no aggregates of plasma-
blastic mononuclear cells. Moreover, reactive germinal centers
and those showing hyaline vascular Castleman features were not
identiﬁed. Kappa and lambda in situ hybridization demonstrated
overall polytypic staining of the plasma cells, and no monoclonal
B cell population was identiﬁed by thorough ﬂow cytometric
analysis. Thus, lymphoma and multicentric Castleman disease
(MCD) were excluded. KSHV latency associated nuclear antigen
(LANA) expression was largely conﬁned to the residual follicles, in
contrast to the pattern observed in MCD (Fig. 1, panel A and B)
(Chadburn et al., 2008; Schmidt et al., 2008). Lambda light chain
staining showed overlap with LANA localization, consistent
with recent reports that suggest preferential KSHV infection oflambda-expressing B cells (Hassman et al., 2011). No overlap of
EBV EBER and KSHV LANA expression was observed.
The patient ultimately died of disease-related complications.
Autopsy conﬁrmed KS of the oral mucosa, skin, small bowel, and
lung (Fig. 1, panel C and D). However, KS could not explain the
massive hepatosplenomegaly, severe anemia and thrombocyto-
penia thought to be secondary to sequestration.
The presence of KSHV in plasma was initially detected by DNA
PCR using primers directed against multiple regions of the viral
genome, speciﬁcally the open reading frames LANA, vFLIP, vGPCR,
Kaposin, and orf69 (Fig. 1, panel E). We chose multiple genes to
increase the speciﬁcity of our assay. These primers were pre-
viously validated on clinical and experimental samples (Dittmer,
2011, 2003). As a positive control for DNA isolation from clinical
specimens we used gapdh primers. The positive control was total
DNA from BCBL-1 cells and the negative control sample was
water. All primers ampliﬁed the predicted size fragment from the
patient sample and positive control, but not the negative control
(the very faint bands in lane 1 and 3 represent primer dimers,
which were smaller than the predicted size). No band was
observed in the ‘no primer control’ lane (Fig. 1, panel E, lane
‘‘.’’). As this assay is a conventional endpoint PCR assay, it is not
quantitative. The brightness of the individual bands is dependent
on their size as well as accumulation. The three longest PCR
products correspond to KSHV genes LANA, vGPCR and gapdh
(Fig. 1, panel E, lanes 1, 4, ‘‘þ ’’). The four very short PCR products
yielded shorter and thus less bright products (Fig. 1, panel E, lanes
2, 3, 5, 6). This demonstrates that KSHV was present in the plasma
of this patient.
To detect free virus, we determined the plasma viral load of
KSHV. The patient had a plasma KSHV viral load of 5,300,000
copies/ml (Viracor-IBT Laboratories, MO). This represents the
highest KSHV viral load on record (Table 1). By comparison KS
patients (Polstra et al., 2003; Sayer et al., 2011) typically have a
mean KSHV viral load of 1000 copies/ml (range 151–26,915), PEL
patients (Simonelli et al., 2009) of 10,284 copies/ml (range 2,558–
36,300) and MCD (Simonelli et al., 2009) of 4,400 copies/ml
(range 600–1,678,000). KS malignancies are AIDS deﬁning, but
rarely associated with high-level virus replication. Average KSHV
plasma viral loads are 1–2 log10 units lower than EBV or HCMV
viral loads even in symptomatic patients (Laney et al., 2007;
Whitby et al., 1995). Hence, for this exceptional case we con-
sidered that the patient succumbed to acute KSHV viremia.
We turned to Illumina-based sequencing to determine the
complete vironome and complete genome sequence of this KSHV
isolate. Total DNA was isolated from white blood cells. No
attempts were made to enrich for viral sequences. IlluminaTM
sequencing was performed by sonication of DNA, primer ligation
and tethered ampliﬁcation, followed by DNA synthesis to yield
435 base reads. To determine the vironome, sequencing reads
were aligned to the reference genomes of all known viruses.
Combining ﬁve individual sequencing runs we obtained a total of
145,179,479 reads of 36 bp (paired), 50 bp (single) and 75 bp
(paired and single) from samples of this patient. A discovery score
(D score) based on the total number of aligned reads and coverage
for each viral genome was computed and subjected to hierarch-
ical clustering. Sequencing reads from samples of known herpes-
virus genome status (two copy EBV – integrated cell line
Namalwa, PEL cell line BCBL-1) were included to calibrate the
virus discovery algorithm. In four of the sequencing runs for this
patient, puriﬁed Guinea Pig CMV DNA was spiked in as an internal
control, and was recovered in sequence alignment for these
samples (Genbank ID: AB592928).
The clustering results are displayed as heatmap and dendro-
grams (Fig. 2, panel A). Positivity is displayed as color (white,
orange, red), with deeper red color indicating a higher D score.
Fig. 1. Patient was positive for Kaposi sarcoma, as conﬁrmed by autopsy, immunohistochemistry, and PCR. (A) LANA (red) and hematoxilin (blue) stain of a lymph node
biopsy at 100 , (B) and at 400 . (C–D, arrows) KS lesions in lung at autopsy, and (E) gel of PCR products conﬁrming KSHV positivity. Isolated PBMC DNA was ampliﬁed
with primers located within the KSHV genes: (1) LANA, (2) vFLIP, (3) K14, (4) vGPCR, (5) Kaposin, (6) Orf69 and GAPDH (‘‘þ ’’) as a reference gene. No primer controls for
each sample are indicated by ‘‘.’’ For comparison, KSHV positive PEL DNA was used (‘‘pos’’), and a non-template control (NTC) was included as a negative control (‘‘neg’’).
Molecular weight markers are shown at the beginning and end.
Table 1
Comparison of viral loads for KSHV-associated diseased, as compared to this case.
Disease Minimum (copies/ml) Maximum (copies/ml) Mean (copies/ml)
KSa 151 26,915 1,000
PELb 2,558 36,300 10,284
MCDb 600 1,678,000 4,400
Patient – – 5,300,000
a KS, Kaposi sarcoma (Polstra et al., 2003)
b PEL, primary effusion lymphoma; MCD, multicentric Castleman disease
(Simonelli et al., 2009)
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number of hits. For the 24 human chromosomes we calculated at
95%CI of 0.03 to 0.07 log10 copies/cell, i.e. two copies per cell.
Our initial screen identiﬁed sequences for 648 genbank entries,
which were classiﬁed as either fungal, viral, protozoal or bacterial.
However, most were present at r2 log10 genome copies/cell,
i.e. fewer than 1 copy per cell. Several bacterial pathogens,
including toxoplasma, were identiﬁed for but could not be
conﬁrmed by standard tests. Mitochondrial genomes were pre-
sent at 1.52 log10 copies/cell, and KSHV was present at 0.23 log10
copies/cell, i.e. at 41 copy per cell.
In total, 22,455 reads aligned to KSHV, resulting in a 9.23 fold
median genome coverage (Fig. 2, panel B). The presence of HHV6a
(but not HHV6b or HHV7) was also revealed upon sequence
analysis. This was surprising, as infection with HHV6a was never
suspected or tested for. Upon retesting of patient plasma we
determined the HHV6 viral load to be 25, 471 copies/ml. We have
investigated the presence of HHV6 (a or b) in 17 additional HIV
patients. Five of these patients had KS, while the remaining 12
were KS negative, but positive for another type of malignancy.
None of the patients were positive for HHV6a, and one patient
was positive for HHV6b, with approximately 1000 cp/ml. This
patient was KS negative, and was positive for Melanoma, a non-
AIDS deﬁning malignancy. This is consistent with the prevalence
in the general population, where HHV6b is much more commonthan HHV6a, which is rarely found in patients (Boutolleau et al.,
2006).
A total of 23,300 reads mapped to HHV6a, yielding 7.65 fold
median coverage (Fig. 2, panel C). Since coverage is a function of
copy number and genome size this demonstrates for the ﬁrst time
HHV8 and HHV6a co-replication in a patient. Both KSHV and
HHV6a DNA sequences were found in roughly equal proportion in
cell-free plasma, where the KSHV plasma viral load was4106.
This would argue that the HHV6a signal, too, stemmed from
replicating virus rather than being horizontally transmitted.
We established uniformity of genome coverage as a second
criterion for virus identiﬁcation. All reads mapped randomly
across the entire length of the HHV8 and HHV6a genomes
(Fig. 2, panel B and C). Reads that aligned to more than one
position, i.e. to repeat region, were randomly placed at only a
single position. In contrast to HHV6a, the few reads that mapped
to the HHV6b genome, all clustered within the terminal repeat
region (data not shown), indicating insufﬁcient coverage to
demonstrate biologically relevant infection.
We derived the whole genome sequence for this KSHV strain
by reference-guided assembly (Genbank ID: JQ619843). The KSHV
consensus sequence was compared to the KSHV reference
sequence (Genbank ID: NC_009333). We did not identify novel
DNA insertions or orfs. We identiﬁed small InDels in speciﬁc
genes (the polymorphic regions of K1 and K15) and in repeat
regions, which is a result of the short read length of the Illumina
platform, but not deletions of entire coding regions or gross
aberrations. Thus no one gene could be linked to the highly
replicative phenotype. These are annotated in the sequence
submission.
To demonstrate relatedness of this primary KSHV isolate to
tumor cell line derived viral sequences, we used ClustalW
(Felsenstein, 1989) using bootstrap analysis with Neighbor-
Joining. The pairwise distances between all the aligned whole
genome sequences were computed using a maximum likelihood
model, the number of replications for bootstrap analysis was
1000. The result is displayed using PHYLIP and demonstrated high
sequence conservation expected of double-stranded DNA viruses
Fig. 2. Nextgen sequencing analysis reveals KSHV and HHV6a coinfection. (A) Heatmap and dendrogram of unsupervised single linkage clustering using a Manhattan
distance matrix. Reads from individual Illumina lanes were aligned to 3608 whole viral genomes in genbank. For each alignment we computed a score based on the
number of hits, coverage and length of the target sequence. (B) Distribution of reads that aligned to the KSHV (NC_003409) genome. Open reading frames are depicted as
arrows. (C) Distribution of reads that aligned to the HHV6a (NC_001664) genome. (D) Phylogenetic tree demonstrating alignment of generated consensus sequence for
KSHV isolated from patient PBMC, in comparison to the previously reported KSHV sequences. BCBL1 sequence was determined from BCBL1 DNA inserted into BAC36 and
cloned. GK18 sequence is from cosmid-cloned DNA originating from a classic KS patient. JSC1 sequence is derived from cellular DNA cloned into BAC219. KS biopsy
sequence is derived from DNA from KS biopsies, partially digested with Sau3A, cloned into lambda phage, and sequenced. BC1 DNA was sequenced from the PEL-derived
cell line, and was cloned into lambda phage and cosmids and sequenced. Our patient sequence is indicated as consensus. (For interpretation of the references to color in
this ﬁgure caption, the reader is referred to the web version of this article.)
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replicative KSHV isolate.
It is difﬁcult to derive genome-wide conclusions from a
comparison of just six genomes. We did note extraordinary
conservation in primary nucleotide and amino acid sequences
among all isolates. For the unique regions of the genome,
approximately one nucleotide change was present per kb and
less than one amino acid per coding regions, as expected for DNA
viruses. The most divergent sequence was the original BC-1,
which was obtained by Saenger sequencing; and which may not
have had the extensive genome coverage afforded by NextGen
based sequencing. The Sau3AKS sequence has deletions in K15
compared to all other sequences, which may be the result of
phage library prep and propagation in Escherichia coli. We
observed variations and gaps in the repeat regions (LIR1, DR1-6,
and TR). These could be the result of misalignment, as short read-
based protocols are known to generate incomplete alignments in
the repeat regions, or they could be the result of genomeevolution. For instance, a 36 bp gap in K1 was conserved in this
sequence, GK18, JSC1 and Sau3A; a 9 bp deletion in DR3 was
conserved in JSC1, BCBL1 and Sau3A. We did not have enough
coverage for a de-novo assembly to unambiguously identify small
DIPs or SNPs for this particular isolate.
Rather than directly testing for each potential pathogen
sequentially, NextGen sequencing technology allowed us to
detect a broad range of viruses, bacteria, fungi, and parasites,
resulting in the detection of additional factors that may be
playing a role in the disease, in this case HHV6a.Discussion
This report highlights NextGen sequencing technology on
patient material to identify infectious agents in a case of a fatal
inﬂammation reaction of unknown origin. Rather than testing for
each potential pathogen individually, sequencing of total DNA in
K.M. Tamburro et al. / Virology 433 (2012) 220–225224plasma and PBMC allowed us to screen for a broad range of
viruses, as well as bacteria, fungi, and parasites (data not shown),
thus resulting in the detection of additional factors that may be
playing a role in patient illness, in this case, HHV6a viremia. This
novel application of Illumina sequencing to assist in patient
diagnosis proved to be a useful tool in determining the cause of
illness and death in this patient.
This represents the ﬁrst documentation of systemic KSHV/
HHV6 co-replication in a patient. Primary HHV6 infection is
mostly subclinical and HHV6 has near 100% sero-prevalence in
the US. HHV6a is primarily associated with exanthema subitum
(Roseola). It has been detected in end-stage AIDS patients, but
these instances are extremely rare. HHV6a DNA has been detected
in a single archival case of a PEL biopsy before (Asou et al., 2000)
but not as free, replicating virus. HHV6a is also found in forms of
reactive lymphoid hyperplasia, such as Crohn’s disease, histiocytic
necrotizing lymphadenitis or Kikuchi–Fujimoto disease in high
prevalence areas, although the present studies are insufﬁcient to
support a conclusive association of HHV6a with these or other
forms of rare reactive lymphoid hyperplasia (Bouvard et al.,
2009). HHV6a can cause KSHV reactivation from PEL cell lines
in culture, as can HCMV (Lu et al., 2005; Vieira et al., 2001).
Whether, in turn, KSHV can stimulate HHV6a replication and/
or its pathogenesis is presently unknown. Both viruses encode as
well as induce cytokines and chemokines, including human IL6
and vIL6, which can induce inﬂammatory symptoms. We surmise
that systemic replication of both viruses, rather than KSHV-
associated neoplasia, led to the clinical symptoms. The clinical
description of SIRS as a cytokine storm is consistent with that of
KICS, which was recently proposed as a new KSHV associated
clinical entity and which is deﬁned by high cytokine production,
particularly of IL6 and the presence of KSHV, but a negative
diagnosis for MCD. We propose that co-infection may have added
to the intensity of KICS. Further studies are necessary to assess
whether HHV6a co-infection is present in other KICS patients, or
if it is necessary for the development of KICS.Conclusions
We have described a fatal case of systemic KSHV and HHV6a
co-viremia in an AIDS KICS patient. Using Next-Gen sequencing,
we were able to generate the ﬁrst KSHV sequence directly from
patient sample, without implementing cloning techniques. This
novel sequence has been deposited into Genbank.Materials and methods
DNA extraction
Genomic DNAwas isolated fromwhite blood cells or plasma using
Wizard SVTM kit (Promega Inc.). All PCR products were the expected
size by gel electrophoresis. No ampliﬁcation was observed without
template. Detailed methods were published previously (Chugh et al.,
2010; Dittmer, 2011). The primer sequences were: (LANA78 50-
GGAAGAGCCCATAATCTTGC, 50-GCCTCATACGAACTCGAGGT (204 bp);
KS10076-1 (vFLIP) 50-ATGCCCTAATGTCAATGCTT, 50-GCGATAGTGTT
GGGAGTGTG (90 bp); K14F 50-TGGTGGGCCTATTTGGGATA, 50-GATG-
CACCGCCCTGCTT (60 bp); orf74F-spl (vGPCR) 50-TGGCCCAAACGGAG-
GATCCTAG, 50-GATGATGAATCCTGGAATGAAACT (232 bp); kaposin
50-CAACAGATAATGGGCCTTGT, 50-AGGTGCAAGCAGACATAATTG;
ORF69 50-TGCAGTGCAGGTACACACCA, 50-GCATCTCGTCGGTGCAGTCT
(61 bp); hu-gapdhF 50-GAAGGTGAAGGTCGGAGTC, 50-GAAATCCCAT-
CACCATCTTC (225 bp). Amplicon sizes are based on the alignment to
HHV8 reference genome NC_009333 and NM_002046 for gapdh.Illumina sequencing
IlluminaTM sequencing was performed by sonication of DNA,
primer ligation and tethered ampliﬁcation, followed by DNA
synthesis to yield 35 base reads. The high viral load allowed us
to use total DNA without virus-speciﬁc enrichment (e.g. Kwok
et al., 2012). To prepare the library, DNA was sonicated, then ends
were repaired and adenylated. Paired end adapters were ligated
to DNA fragments and puriﬁed via gel electrophoresis excision
and QIAGEN gel extraction kit (QIAGEN, part #28704). Ligated
products were ampliﬁed using PCR prior to sequencing run.
Sequencing was performed using a variety of conditions: paired
end 276 cycles. Additional runs include 50 bp single reads, 36
bp paired reads, and 76 bp single reads. The reads were aligned to
human, viral (Genbank ID: NC_003409 for KSHV, NC_001664 for
HHV6a) and microbial genomes using CLCbio software (CLCbio
Inc.) and EMBOSS (Rice et al., 2000).
By computing the number of sequence reads that aligned to a
given pathogen genome against the genome size, we estimated
the relative frequency of the pathogen. For human DNA, we
obtained on an average 0.005 reads/bp; more for mitochondrial
genomes, since there are multiple mitochondria per cell genome.
For KSHV and HHV6a we obtained almost equal coverage with
0.003 reads/bp. In contrast, HHV6b coverage was 10 fold lower
(5104 reads/bp), as was EBV (3105 reads/bp) and (HCMV
8106 reads/bp) coverage. Our discovery score D takes a linear
combination of the number of hits, the target genome and
coverage. It was calculated for each genbank entry and each
sample and subjected to unsupervised clustering using R v2.8.0
(Maindonald and Braun, 2007).Phylogenetic comparison
To compare our KSHV isolate to the existing whole genome
data, we used clustalW and the following sequences: BCBL1
(Genbank ID: HQ404500), JSC1 (Genbank ID: GQ994935), KS
biopsy (Genbank ID: U93872), BC1 (Genbank ID: KSU75698),
and GK18 (Genbank ID: NC_009333). Our patient sequence is
indicated as Consensus and submitted as Genbank ID: JQ619843.Immunohistochemistry
A formalin ﬁxed, parafﬁn-embedded lymph node was sec-
tioned and dehydrated through a series of ethanol washes.
Sections were then stained using a rat monoclonal anti-LANA
antibody (Advanced Biotechnologies Inc.) diluted at 1:1000, and
VectastainTM (Vectorlabs Inc.) kit, counterstained with hematox-
ylin, and rehydrated through a series of xylene washes before
being ﬁxed with a xylene-based mounting solution. Images were
collected on a LEICA DM LS microscope with DFC480 camera.Acknowledgments
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